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What is already known about this topic? 
 Cellulitis can have a significant impact on the physical and psycho-social wellbeing 
of patients.  
 There is currently no consensus on what outcomes should be measured in cellulitis 
trials. This makes it difficult to summarise treatment effects in meta-analyses.  
 
What does this study add? 
 This review is the first to combine and compare clinical outcomes in randomised 
controlled trials (RCTs) assessing treatment and prevention of cellulitis with 
outcome themes deemed important to patients and health care professionals.  
 We have highlighted the disparity in clinical outcomes published in these RCTs and 
the lack of patient reported outcomes. 
 Following the COMET initiative, we suggest that homogenous outcomes should be 
sought and specified for future research in cellulitis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
 
Background: There is an emerging need to develop consistent outcomes in clinical trials 
to allow effective comparison of treatment effects. No systematic review has previously 
looked at the reporting of outcome measures used in randomised controlled trials (RCTs) 
on treatment and prevention of cellulitis (erysipelas).  
 
Objectives: The primary aim of this review was to describe the breadth of outcomes 
reported from RCTs on cellulitis treatment and prevention. The secondary aim was to 
identify outcome themes from patient and health care professionals’ feedback from a 
cellulitis priority setting partnership (PSP).  
 
Methods: We conducted a review of all outcome measures used in RCTs from two recent 
Cochrane reviews. Free text responses from a cellulitis priority setting survey were used 
to understand the perspectives of patients and healthcare professionals.  
 
Results: Outcomes from 42 RCTs on treatment of cellulitis and six RCTs on prevention of 
cellulitis were reviewed. Only 28 trials stated their primary outcome. For trials assessing 
treatment of cellulitis, clinical response to treatment was categorised in 25 different ways. 
Five of these trials used an outcome that was in accordance with FDA guidance and only 
four trials incorporated either quality of life or patient satisfaction. For trials assessing 
prevention of cellulitis, recurrence was the key outcome measure. From the cellulitis PSP, 
prevention of recurrence, clinical features and long-term disease impact were the most 
important outcome themes for patients.  
 
Conclusions: We have shown that in cellulitis treatment and prevention research, there 
is significant heterogeneity in clinical outcomes, inadequate focus on patient-reported 
outcomes, and a disparity between what is currently measured and what patients and 
healthcare professionals feel is important.  We recommend that future cellulitis treatment 
trials consider the use of longer-term outcomes to capture recurrence and long-term 
morbidity, as well as short-term resolution of acute infection. 
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Introduction 
 
Cellulitis is an acute, potentially serious bacterial infection of the cutaneous and sub-
cutaneous tissue, usually occurring on the lower limb. The most common causative 
organism is group A streptococcus (streptococcus pyogenes)1  which causes a spreading 
area of erythema, tenderness and swelling. The illness can be complicated by ulceration, 
purulence and progression to systemic disease in severe cases. Erysipelas is 
characterised by a superficial, well-demarcated area of inflammation, whilst cellulitis 
often extends to the subcutaneous tissue2. It is often difficult to distinguish between 
them clinically; therefore for the purpose of this review we have used cellulitis as the 
umbrella term for cellulitis, erysipelas and skin and soft tissue infection, which reflects 
current practice. 
 
Cellulitis poses a significant health burden to the NHS: during 2014-15 in England, 
114,190 patients were treated in hospital for cellulitis with a median length hospital stay 
of 6 days3. In addition to short-term signs and symptoms, the disease can have a 
significant long-term impact on patient’s physical and mental health4. In certain groups 
of patients there are high levels of recurrence of cellulitis arising from repeated damage 
to the lymphatic system and the presence of certain risk factors 2.  
 
Despite the impact of the disease, there are few well-conducted trials looking into the 
treatment and prevention of cellulitis5,6. It has been reported that clinical assessment of 
cellulitis many not capture the patient’s experience, and may be unreliable in reflecting 
real effects for patients7. 
 
Defining standard, measurable outcomes is essential for well-designed, robust clinical 
trials, to provide trial results can be reliably compared8. Outcomes need to be 
meaningful and relevant for service-users, including patients and clinicians, in order to 
make a long-term difference to future practice. 
 
It has been recognised that many outcomes in clinical trials lack sufficient validation and 
there is support for development of core outcome sets (COS) for trials to address this 
issue, as proposed by the COMET initiative8. A COS is an agreed set of outcomes that 
should be measured and reported, as a minimum, in all clinical trials in a specific area of 
health care9. The initial stage in developing a core outcome set is to identify what 
outcomes are available, and to establish which are most important and relevant for 
healthcare users10,11. 
 
The Food and Drug Authority (FDA) have attempted to address the lack of consistent 
outcomes for clinical trials of Acute Bacterial Skin and Soft tissue infections (ABSSIs). In 
2013 they updated their guidance on endpoints in such trials which states the primary 
outcome should be: % reduction in lesion size, measured at 48 to 72 h compared to 
baseline12. However, this recommendation is largely based on historical trial data dating 
to pre-antibiotic era and has undergone incomplete validation13. 
   
There have been no systematic reviews assessing outcome measures used in cellulitis 
trials. The main aim of this review was to describe all the outcome measures reported in 
randomised control trials (RCTs) on the treatment and prevention of cellulitis. The 
secondary aim was to identify outcome themes from patient and health care 
professionals’ feedback from a cellulitis priority setting partnership (PSP)14.  
 
 
 
 
 
 
Methods 
 
Study 1: Review of outcome measures in RCTs for the treatment and prevention 
of cellulitis 
 
Search strategy  
 
This review included all RCTs that were included in two Cochrane reviews: Interventions 
for the prevention of recurrent erysipelas and cellulitis5 , published in June 2017, and the 
Cochrane update: Interventions for the treatment of cellulitis and erysipelas (awaiting 
publication but obtained from personal communication with authors). Studies that 
assessed treatment or prevention of cellulitis, erysipelas or skin and soft-tissue infection 
were included in this review. A search of COMET and PROSPERO was performed to 
ensure that no existing core outcome initiatives of thematically similar reviews were 
already registered. 
 
Data regarding treatment complications, adverse events and side effects were not 
collected as this data is routinely collected in drug trials was not an aim of this review.  
 
The study protocol for this review is available to view on the Centre of Evidence Based 
Dermatology website15 
 
Data extraction and assessment of bias 
 
Reported outcomes were extracted using a standardized template that was piloted prior 
to use. If the outcome measures were not clearly stated in the methods section of the trial 
report, but were described in the results section, then these were included. 
 
Details of outcome measures were extracted from each paper by two independent 
researchers (ES and MP). Any disagreements were resolved by two further independent 
researchers. 
 
Data extracted were:(i) demographics of trial (author and date of publication) (ii) trial 
type: treatment/ prevention of cellulitis, drug/ non-drug, (iii) whether primary outcome 
was stated (iv) total number of outcomes per trial (v) whether outcomes were in line 
with FDA guidance on skin infections (vi) additional comments on outcomes used in trials 
e.g. justification of outcomes (vii) Broad outcome domains: clinical, microbiological, 
biochemical, treatment-related, patient-focused, additional outcomes. For each outcome 
domain, further definitions were used for the specific outcomes measured e.g. 
cure/failure/response, length of hospital stay, quality of life. Additionally, for clinical 
outcome, the specific clinical features that were assessed as part of the outcome were 
identified e.g. erythema, swelling, warmth (viii) definition of each outcome (ix) how the 
outcome was assessed ix) scales used (xi) outcome assessor e.g. nurse/clinician/patient 
(xii) Timing/frequency of assessment. 
 
Storage and analysis of all the data was undertaken by the lead researcher (ES) using 
Microsoft Excel, 2010, CEBD. Data are presented descriptively, and results reported 
separately for cellulitis treatment trials and prevention trials. 
 
Study 2: Understanding patient and healthcare professionals’ perspectives 
 
Using free text data collected during a Priority Setting14 we sought to identify outcomes of 
importance to patients and healthcare professionals. Responses were submitted by 401 
survey participants (171 patients/carers, 217 healthcare professionals, 13 other). 
Participants were asked the following: “What questions about the diagnosis, treatment or 
prevention of cellulitis would you like to see answered by research?” Data relevant to 
outcome measurement were extracted from the free text responses and used to identify 
key outcome themes using the word repetition technique16. 
 
  
Results 
 
From the two Cochrane reviews, 48 trials were identified and included in the final analysis. 
This included 42 RCTs assessing acute treatment of cellulitis and six RCTs assessing 
prevention of cellulitis. No studies were excluded. The total number of outcomes measured 
per trial ranged from one to eight outcomes, across six different outcome domains (Figure 
1). Only 28 (58%) trials stated the primary outcome. Two papers assessed non-
pharmacological treatments for cellulitis; one reviewed the use of vibration therapy and 
the other an alternative therapy: sodium selenite. Six trials evaluated treatment strategies 
for skin and soft-tissue infections but did not analyse results for cellulitis separately.  
However, data from these papers were included in this review, to maximise capture of 
outcomes.  
 
RCTs assessing treatment of cellulitis 
 
Clinical outcomes 
  
All trials assessed at least one clinical outcome. Of the RCTs assessing treatment of 
cellulitis, clinical response was categorised according to a range of definitions (Table 1) 
with the majority of papers classifying response according to “cure”, “failure” or 
“improvement”. The timing of the clinical assessment was variable. Some recent trials 
assessed clinical response at an early time-point, 2-3 days after treatment initiation. 
However, most trials assessed response at a “test-of-cure (TOC)” visit, which ranged 
from 2 to 42 days after the end of treatment (Table 1). A successful clinical response or 
“cure” was defined most commonly as either “complete resolution of presenting signs 
and symptoms”, or “resolution of the infection to an extent that no further antibiotic 
therapy was required” (Table 2). Four (10%) trials included “absence of recurrence” of 
infection as part of the definition of a successful clinical response.  
 
There were 10 different signs and symptoms of infection used to describe clinical 
response across the trials (Figure 2). The most commonly assessed clinical feature was 
erythema. Of 34 trials that assessed erythema, six (18%) assessed this numerically, 
measuring the diameter or area of erythema, six (18%) graded the erythema on a 
severity scale (Figure 3); and 13 (38%) used “clinical assessment/ evaluation” without 
further detail of the methods used.  
 
Sixteen (38%) of trials assessed at least one biochemical marker as part of clinical 
response to treatment. Of these, the most commonly assessed markers were white cell 
count, erythrocyte sedimentation rate and c-reactive protein. 
 
Microbial outcomes 
    
Twenty-four (57%) trials included a microbial outcome, assessed using either blood or 
wound culture. The majority of trials categorised microbial response according to 
complete/presumed eradication, persistence/presumed persistence and indeterminate/ 
not evaluable (Table 4). Of the trials assessing a microbial response, the timing and 
frequency of assessment was either not stated or unclear in 18 (42%) trials.  
 
Treatment-related outcomes 
    
Sixteen (38%) trials assessed a treatment-related outcome. These included: duration of 
antibiotic treatment (13), number of doses of antibiotic (2) and serum antibiotic 
concentration (1). One trial used “number of doses of antibiotic until clinical response” as 
the primary outcome for the study.  
   
Patient-focused outcomes 
    
Four trials included patient-focused outcomes in their methodology. One trial assessed 
Quality of Life (QoL) using the EuroQol-5 dimensions (EQ-5D) questionnaire. Two 
assessed patient’s impression of improvement of cellulitis: one using the patient Global 
Impression of Improvement scale and one using predefined categorical statements: 
improved, stayed the same, worsened.  One paper assessed patient satisfaction with 
treatment received, assessing each of the parameters: convenience, effectiveness and 
overall satisfaction on a scale of 0-4. Eleven (26%) trials assessed patient-reported pain 
(Table 3). 
 
 
FDA guidance 
    
Five (12%) trials assessing treatment of cellulitis that were published from 2011 
onwards had their primary outcome in line with FDA guidance.  
 
RCTs assessing prevention of cellulitis 
 
The primary outcome of trials assessing prevention of cellulitis was either: number of 
episodes of recurrence or time to recurrence of cellulitis for all six RCTs17-22. Three (50%) 
of the trials specified the clinical features to be used in assessing an episode of recurrence. 
Follow-up time varied from 3 months to 3 years. Two (33%) papers explained how patients 
were monitored during the follow-up period: via routine telephone calls, 3-monthly during 
the treatment phase and 6 monthly during the follow-up phase It is worth noting that the 
PATCH I and II trials intended to collect data on the impact of cellulitis on QoL, however 
this was abandoned due to technical difficulties around timing of assessments in recurrent 
episodes21. 
 
Additional outcomes 
    
Additional outcomes measured in all trials (assessing both treatment and prevention of 
cellulitis) included: length of hospital stay (ten trials) and cost-related outcomes (five 
trials). 
 
Outcome themes from the cellulitis PSP 
 
A total of 846 uncertainties were submitted during the PSP survey. These data were 
reviewed for outcome themes, and 254 (30%) responses included reference to outcomes 
of importance to participant. From these responses, 263 outcome themes were identified 
(some responses contained more than 1 outcome theme), of which 73 (28%) were from 
patients and 190 (72%) from healthcare professionals. Prevention of recurrence was the 
most frequently stated outcome theme of importance from both patients and healthcare 
professionals (Figure 4). “Treatment-focused” outcomes such as: length of acute and 
prophylactic antibiotic therapy and the use of objective markers to assess treatment 
response, were also key priorities for healthcare professionals. Assessment of clinical 
features (erythema, swelling and pain most commonly) and long-term morbidity/mortality 
were the next most important outcomes for patients. Surprisingly, only 2% of all outcome 
themes extracted focused on patient-orientated factors such as quality of life and 
treatment satisfaction.  
 
 
 
 
Discussion 
 
Main findings 
 
1. Variability in clinical outcomes 
 
This review highlights the significant variation of outcomes which are currently used in 
cellulitis trials, suggesting that efforts to streamline and develop a consensus-driven core 
outcome set would be valuable.  
 
Clinical response to treatment was categorised in 25 different ways in the 42 treatment 
trials, and “cure”/ “success” or “resolution”, had 18 different definitions that were 
measured over a range of timescales, from day 2 to day 35 after the end of treatment 
period. The majority of trials defined “cure” according to complete or partial resolution of 
presenting signs and symptoms of infection. However, the specific signs and symptoms of 
infection assessed, such as erythema, swelling and warmth were often poorly defined. Up 
to 10 different signs and symptoms of infection were each used by at least one trial to 
assess treatment response. This reflects the general lack of consensus in outcome 
assessment for cellulitis. 
 
Some of the more recent trials used “early clinical response” as the primary outcome, 
defined as: “cessation of lesion spread (measured as the product of the length x width of 
lesion) 48-72 hr after treatment initiation”. Assessing treatment response at this earlier 
time-point may increase reliability of the measurement of drug effect, because the 
outcome is not confounded by natural improvement of disease23. Moreover, this endpoint 
is in line with the 2013 FDA guidance recommending early clinical response as the 
primary outcome12.  
  
2. Inadequate patient orientated outcomes 
 
Patient-focused outcomes such as patient-reported pain, treatment satisfaction and 
quality of life were rarely reported. We know that cellulitis has a significant impact on 
physical and psychological health, as well as activities of daily living and quality of life4, 
yet this significance is not reflected in the outcomes from the cellulitis trials published to 
date. Importantly, the survey results suggest that recurrence and long-term disease 
impact are important aspects to patients. To date, treatment trials have tended to be of 
short duration and focus on resolution of symptoms associated with the acute episode. 
This is not surprising given the cost and methodological complexities associated with 
longer-term trials, but may require greater consideration when planning future studies.  
 
There were far more treatment trials than prevention trials, which again suggests an 
imbalance favoring short-term outcomes. More trials that address the prevention of long-
term morbidity and recurrence are needed, so that treatment strategies can be developed 
that have a long-term beneficial impact for patients. 
 
In contrast to patient responses, the survey results revealed the most important outcomes 
to healthcare professionals were: objective markers of disease response, length of 
antibiotic treatment and prophylaxis (in addition to recurrence). This is perhaps not 
surprising, given that healthcare professionals are responsible for both prescribing and 
objective assessment of treatment effect, rather than a subjective experience of disease.  
 
 
 
 
3. Limited use of microbial outcomes 
 
The use of blood or wound cultures in cellulitis management is debatable. Microbial 
outcomes are a poor indicator of treatment success as their yield is often low, even in 
the presence of infection24 and can be adversely affected if patients have been pre-
treated with antibiotics. Furthermore, microbial cultures do not correlate well with 
severity of signs and symptoms or patient experience.24. This outcome measure is also 
of limited relevance to patients. However, the increasing incidence of antimicrobial 
resistance means that other indicators of resistance, such as the incidence and severity 
of other bacterial infections, may be important to collect. 
 
Strengths and weaknesses 
 
This review summarised the breadth of outcomes reported in published RCTs and analysed 
these alongside outcomes considered important by patients and healthcare professionals. 
 
Since data on the views of patients and healthcare professionals were originally collected 
for another purpose (defining the research agenda for cellulitis research), they may not 
be as reflective of the results as if respondents had been asked specifically about research 
outcomes. Further qualitative work is required to replicate our findings and to full ascertain 
the perspectives of all key stakeholders. 
 
The quality of included studies was not assessed as this was not the aim of this review, 
however many studies were poorly reported, making it difficult at times to establish a 
detailed understanding of the outcome measures used.  
 
Due to time and resource limitations, included studies were identified from two recently 
updated Cochrane reviews. These were chosen because they are both up-to-date and 
sufficiently broad (covering any “treatment” and “prevention” of cellulitis) to gain the 
breadth of outcome data we aimed to capture. It is possible that more recent RCTs on 
cellulitis treatment and prevention have since been published.  
 
Generalisability  
     
The included trials were conducted in eight single countries and nine in multiple countries. 
This review captures a representative snapshot of existing outcomes measures used in 
cellulitis research. Others have highlighted similar variability in outcome measure 
instruments used in skin diseases such as eczema25, vitiligo26 and acne27.  
    
  
 
Conclusion  
     
Outcome measures for cellulitis should not only be consistent, to allow clinical trials to be 
adequately compared, but should be reflective of real impact in patient’s day to day 
lives. This review has highlighted that in cellulitis research currently there is a lack of 
consensus over what should be measured, how that should be measured and over what 
time-frame. Future research should work towards validating current outcomes with a 
view to developing a COS for cellulitis. Ideally this would include patient-reported 
outcomes and a long-term outcome measure, such as recurrence, to account for the 
chronicity of the disease that is important to many patients. Currently, researchers 
should seek to ensure outcomes are in line with FDA guidance specific to acute bacterial 
skin and soft tissue infections. 
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Results Tables 
 
Table 1. Categorisation of clinical response and timing of assessment 
 
Categories used Timing of assessment  Number of trials 
Cure, failure Variable28  
Day 25-35 (follow-up)29  
Day 7-14 after EOT (TOC)30  
Day 14-21 after EOT (TOC)31  
1 month after EOT32 
5 
Cure, improvement, failure, indeterminate Unclear33  
Day 7 after EOT34  
Day 4-9 after EOT 35 
EOT (variable)36 
4 
Cure, failure, indeterminate Day 1 after EOT, Day 8-15 after EOT (TOC)37  
Day 7-14 after EOT38  
Day 10-42 after EOT (TOC)39   
EOT, Day 8-15 after EOT (TOC)40                      
4 
Cure, improvement, failure Day 11 after treatment initiation41  
EOT (variable)42  
48-72 hrs after completion of IV therapy43 
3 
Success, failure  48-72hrs after treatment initiation, Day 14-15 
(EOT)44  
Day 14, Day 28 after treatment initiation45  
Day 7 after treatment initiation46 
3 
Relapse/ recurrence 21-35 days after EOT37,40   
Day 28-35 after EOT (TOC)31  
Unclear42 
4 
Satisfactory, unsatisfactory Unclear47, 48, 49 3 
Cured, not cured Day 10-14 after treatment initiation (TOC), 2-
14 days after EOT (short-term follow-up)50  
Day 4-11 after EOT  51 
Day 12 (EOT), Day 7-10 after EOT, Day 40 (1 
month follow-up)52                                          
3 
Cure, failure, not evaluable Day 7-14 after EOT (TOC)53, 54  
Day 28-35 after EOT (TOC)54 
2 
Cure + lesion regression Day 14-17 (EOT)29 1 
Cure, failure, relapse Day 7-14 after EOT (TOC)55 
Satisfactory (cure), unsatisfactory 
(failure/relapse) 
Within 24 hrs last dose (EOT), Day 7-14 after 
EOT56 
1 
Cure, recurrence  1 month after EOT36 1 
Clinical success (cure, improvement), no 
improvement, failure 
48-72 hr after treatment initiation57 1 
Failure After 24 hrs of treatment58 1 
Successful response, stable response, failure 48-72 hr after treatment initiation46 1 
Success (cure/ improvement), failure, 
indeterminate/ not assessable  
Day 11 (EOT), Day 7-14 after EOT46  
Day 7-16 after EOT (TOC)59 
2 
Cure, improvement Day 7-14 after EOT60 1 
Success, improvement, failure Day 7-14 after EOT61 1 
Responder, non-responder Day 3 of treatment61 1 
Responder, non-responder, indeterminate 48-72 hrs after treatment initiation62 1 
Responder, failure Day 11 (EOT)62 1 
Satisfactory, failure, indeterminate, 
unevaluable 
Unclear63 1 
Cure, improvement, failure, relapse Unclear64 1 
Failure, recovery Daily for 10 days of treatment65 1 
TOC= test of cure. EOT= End of Treatment 
 
 
Table 2. Definition of "cure"/"success"/ "satisfactory" response across trials 
Definition  Number of trials 
Resolution of all signs and symptoms of the infection/ improvement to such an extent 
that no further antimicrobial therapy was necessary 
1030,31,37,39,40,53-56,61 
Complete resolution of presenting signs and symptoms 1033-35,38,41-43,48,51,59 
Early clinical response: cessation of lesion spread + afebrile± 438,44,50,62 
>20% reduction in lesion area (length x width of erythema, oedema, induration)±  146 
i) absence of fever ii) no increase in area of erythema plus absence of fever iii) no 
increase in area of erythema, no increase in area of swelling and the absence of fever 
iv) >20% reduction in area of erythema 
161 
Resolution of symptoms other than slight residual erythema/oedema 132 
Clinical signs and symptoms resolved with no evidence of active infection at the time 
treatment was discontinued and no evidence of relapse 
164 
(i) Complete resolution of signs and symptoms of soft-tissue infection that was 
sufficient enough to result in either discontinuation of all antibiotic therapy or switch 
to the use of oral agents (ii) with no recurrence at the same site in 1 month 
136 
All signs and symptoms of the infection that were present before therapy were 
improved or had resolved and no new signs or symptoms of the infection were 
present at the post-treatment follow-up 
149 
Days until no advancement of the area of cellulitis 166 
Days until no remaining flush/elevation of body temperature >37.8 degrees Celsius 
on that day 
167 
A score of 0 for erythema, oedema and pain and a normal temperature 165 
Time to resolution of erythema, oedema, pain and temperature, without additional 
antibiotics 
128 
Body temperature <37.5 degrees, complete regression of local/general signs of 
severity and disappearance of the cutaneous plaque  
129 
Lesion size, defined as its length times its width, decreased from baseline, 
temperature was ≤ 37.6°C, fluctuance and localized heat/warmth were absent, and 
tenderness to palpation and swelling/induration were no worse than mild; for patients 
with a wound infection, the purulent drainage was to be improved and no worse than 
mild 
144 
Disappearance of warmth and tenderness at the site of infection, with substantial 
improvement in erythema and oedema, even with mild residual erythema, 
hyperpigmentation or oedema, not requiring further antibiotic therapy at day 14, and 
without symptom recurrence at day 28 
145 
Signs and symptoms disappeared or improved or signs and symptoms disappeared or 
improved during therapy but recurred 
147 
Improvement in signs and symptoms 163 
Not defined 252,60 
± Outcomes in line with FDA guidance: cessation of lesion spread (measured as the product of the length x 
width of lesion) 48-72 hr after treatment initiation 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Method of assessment of patient-reported pain 
Method of assessment Trials  
0= absent, +/1 = moderate,  ++/2 = marked/severe  328,29,65 
100mm VAS scaleƗ                                                      346,58,60 
10cm VAS scale± 166 
Faces rating scale±  146 
Severity rating: none, mild, moderate, severe  168 
Likert pain scale (0-10)  145 
McGill pain score 169 
Brief pain Inventory 157 
Ɨ0= “no pain” and the 100 = “worst pain”. ±10 point scale. 0 = “no pain” and 10 = “worst pain you can 
imagine” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Categorisation of microbial outcomes 
 
Microbial response Definition Number of trials 
Complete eradication Absence of culturable material/pre 
treatment pathogen from the original 
infection site by the end of therapy 
1730,31,33,35-37,39,41,46,49,51,53-
55,59,63,64 
 Not defined 350,60,61 
Presumed eradication Adequate source specimen not available 
to culture but patient was assessed as a 
clinical cure/responded 
930,31,37,39,46,53,54,59 
 Not defined 350,60,61 
Partial eradication Absence of some, but not all pre-
treatment pathogens at the end of 
therapy 
233,64 
Success Documented/presumed eradication of 
the baseline pathogen 
134 
Cure The pathogen was eliminated with a 
clearing of inflammation, or the infection 
recurred with a new pathogen 
147 
Eradication of causative pathogen or no 
materials for culture due to clinical 
success 
143 
Persistence Growth of the pre-treatment pathogen in 
a culture taken at the post-treatment 
visit 
1230,31,33,36,39,47,49,53,55,59,63,64 
Absence of appropriate culture material 
in a clinical failure 
139 
Eradication of original pathogen with a 
post-baseline positive culture with a new 
pathogen requiring treatment 
139 
 Not defined 834,35,37,46,50,51,54,61 
Presumed persistence No pathogen identified in a patient who 
was assessed as clinical failure 
330,31,53 
 Not defined 446,50,54,61 
Superinfection/ new 
infection 
Emergence of a different pathogen 
organism during or at the end of therapy 
330,33,36 
Pathogen different from that isolated at 
baseline in presence of  signs/symptoms 
of infection 
331,53,59 
 Not defined 350,54,61 
Failure Lesion persisted with significant numbers 
of the original pathogen, or lesion 
improved but recurred with a culture 
that was positive with the same 
pathogen 
147 
Persistence/ presumed persistence of 
causative pathogen 
240,43 
Recurrence Initial clearance of pre-treatment 
pathogen, same pathogen reappeared 
during the follow-up period 
155 
Colonisation Pathogen isolated in absence of clinical 
signs/ symptoms of infection 
153 
Indeterminate/ not 
evaluable  
Unevaluable results/ response not fitting 
any other category  
1133,34,37,39,40,43,53,54,59,61,64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 
Figure 1. Broad outcome domains used across trials 
 
±Explanation of outcome categories. Clinical: signs and symptoms of infection assessed as a measure of 
treatment effect, Microbial: growth or elimination of organisms at the site of infection or in blood cultures as a 
measure of treatment effect, Biochemical: blood markers measured before and after treatment, Treatment-
related: e.g number of doses/ length of antibiotic therapy used as an outcome, Patient-focused: e.g QoL 
effects in response to treatment 
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Figure 2. Signs and symptoms of infection assessed in clinical response 
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Figure 3. Method of assessment of erythema  
 
Ɨ10cm VAS scale: ranging from skin normal colour, no inflammation at 0.0 to skin very red and inflamed at 
10.0 
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Figure 4. Outcomes themes of importance extracted from participant feedback in the Cellulitis 
Priority-setting Partnership 
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